此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Progesterone for Smoking Relapse Prevention Following Delivery

2018年1月12日 更新者:Yale University

Progesterone for Postpartum Smokers: Feasibility, Breastfeeding and Infant Safety

Smoking is the main preventable cause of mortality in Western countries, contributing to over 430,000 deaths a year in the U.S. alone. Clinical and epidemiological studies show that women often decrease smoking in pregnancy, when progesterone levels are high. However, at least half resume pre-pregnancy smoking levels within weeks after delivery and when progesterone levels drop.

Data from preclinical and clinical studies suggest that progesterone may be effective in preventing relapse to smoking in non-postpartum women. Prior work has shown that progesterone decreases both craving for cigarettes and the subjective rewarding effects of smoking among recently abstinent female smokers. These findings led us to hypothesize that progesterone may have efficacy as a relapse prevention treatment for postpartum women.

We propose an 8-week, randomized pilot study to evaluate the safety and initial efficacy of progesterone. This will be a feasibility study that will compare progesterone to placebo for relapse prevention in 40 postpartum smokers. We will assess the feasibility and safety, including the potential effects on breastfeeding and infants exposed via breast milk, in addition to 7-day point prevalence of smoking abstinence after 8 weeks of treatment and at follow-up, 3-months after the end of the protocol.

研究概览

研究类型

介入性

注册 (实际的)

41

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Connecticut
      • New Haven、Connecticut、美国、06510
        • Yale School of Medicine Dpt of Psychiatry

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 42年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Need to be within 3 weeks of delivery because relapse to smoking happens early after childbirth
  • Aged 18 to 42 years
  • history of smoking, with smoking and other nicotine product abstinence achieved in the final two months of pregnancy and at delivery
  • In good health as verified by medical history
  • Using acceptable birth control methods other than hormonal contraceptives that contain progestins
  • Have biologically confirmed abstinence from tobacco and other nicotine products at randomization

Exclusion Criteria:

  • A history of major medical illnesses including liver diseases, suspected or known malignancy, thrombophlebitis, liver failure, or other medical conditions that the physician investigator deems will make study participation unsafe for the subject
  • Current or past history bipolar disorder or schizophrenia or current diagnosis of major depression, panic disorder or post-traumatic stress disorder
  • Dependence on and/or abuse of alcohol or other drugs of abuse in the month prior to randomization into the trial
  • the presence of suicidal or homicidal ideation, or significant impairment of social or occupational functioning, either at study baseline during the evaluation process, or during participation in the trial
  • inability to speak Spanish or English (our group is bilingual)
  • plans to move out of the area within 8 months after study screening since this will make follow-up difficult
  • Inability to understand study procedures or provide informed consent
  • Currently undergoing treatment with another pharmacological agent for smoking cessation
  • pending legal case that may result in incarceration since this would force abstinence and impede follow-up;
  • Pending case with child protective services that might lead removal of infant from mother's custody, as this would impede breastfeeding and infant follow-up
  • Unwilling to accept randomization
  • Subsequent pregnancy since that would be another source of progesterone
  • An acute general medical condition that would require imminent re-hospitalization since this would enforce abstinence (women may be randomized if they are discharged and still within the recruitment window)
  • Allergy to progesterone or peanuts (vehicle for micronized progesterone)
  • Currently undergoing treatment with ketoconazole or any other known strong CYP3A4 inhibitors

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:placebo
In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
实验性的:Progesterone
In this group women will receive oral micronized progesterone twice a day.
oral micronized progesterone

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility of Progesterone as a Relapse Prevention Intervention for Postpartum Women With Pre-conception Smoking: Adherence to Treatment
大体时间:8 weeks
Feasibility will be shown by high adherence to treatment condition assessed by doses of study medication taken
8 weeks
Feasibility of Progesterone as a Relapse Prevention Intervention for Postpartum Women With Pre-conception Smoking: Retention
大体时间:From randomization to 3-month follow-up: up to 5 months
Feasibility in retention will be shown by at least 70% of women randomized to the progesterone group reamaining in the study at the 3-month follow-up
From randomization to 3-month follow-up: up to 5 months

次要结果测量

结果测量
措施说明
大体时间
7-day Point Prevalence of Abstinence at End of Treatment (Week 8)
大体时间:Week 8 of the trial period
Abstinence was defined as self-report of no smoking in the past 7 days confirmed by a negative urine cotinine test (urine cotinine <100 ng/ml).
Week 8 of the trial period

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ariadna Forray, MD、Yale School of Medicine

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2013年11月1日

初级完成 (实际的)

2016年8月1日

研究完成 (实际的)

2016年9月1日

研究注册日期

首次提交

2013年10月17日

首先提交符合 QC 标准的

2013年10月24日

首次发布 (估计)

2013年10月30日

研究记录更新

最后更新发布 (实际的)

2018年1月17日

上次提交的符合 QC 标准的更新

2018年1月12日

最后验证

2018年1月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅